A study to validate an antiemesis questionnaire tool in blood cancer patients receiving chemotherapy

ABSTRACT: Primary outcome(s): 1.Content validity and Internal consistencyTimepoint: 1. One month

DISEASE(S): Follic,Chronic Myeloid Leukemia, Bcr/abl-positive,A- Cutaneous T-cell Lymphoma, Unspecified,Angioimmunoblastic T-cell Lymphoma,Extranodal Marginal Zone B-cell Lymphoma Of Mucosa-associated Lymphoid Tissue [malt-lymphoma],Cutaneous Follicle Center Lymphoma,Acute Leukemia Of Unspecified Celltype,Acute Myelomonocytic Leukemia,Acute Myeloblastic Leukemia,Adult T-cell Lymphoma/leukemia (htlv-1-associated),Anaplastic Large Cell Lymphoma, Alk-positive,Acute Promyelocytic Leukemia,Acute Megakaryoblastic Leukemia,Acute Erythroid Leukemia,Acute Monoblastic/monocytic Leukemia,Extramedullary Plasmacytoma,Blastic Nk-cell Lymphoma,Diffuse Follicle Center Lymphoma,Atypical Chronic Myeloid Leukemia,bcr/abl-negative,Acute Myeloid Leukemia With 11q23-abnormality,Chronic Leukemia Of Unspecified Cell Type,Chronic Lymphocytic Leukemia Of B-cell Type,Burkitt Lymphoma,Acute Panmyelosis With Myelofibrosis,Diffuse Large B-cell Lymphoma,Chronic Myelomonocytic Leukemia,Enteropathy-type (intestinal) T-cell Lymphoma,Acute Lymphoblastic Leukemia [all],Anaplastic Large Cell Lymphoma, Alk-negative,A- Acute Myeloid Leukemia With Multilineage Dysplasia,Extranodal Nk/t-cell Lymphoma, Nasal Type

PROVIDER: 2598724 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR